Loading stock data…
$1.00-0.03 (-2.91%)
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
Veraxa Biotech AG in the Healthcare sector is trading at $1.00 with a market capitalization of $281M. The stock is currently near its 52-week low of $0.99, remaining 86.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 |
|---|---|---|---|
| Total Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Income | — | — | — |
| Net Income | — | — | — |
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary t...